Profile data is unavailable for this security.
About the company
Stryker Corporation (Stryker) is a medical technology company. It offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. It operates through two segments: MedSurg and Neurotechnology, and Orthopedics and Spine. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products. It also develops neurointerventional devices for the treatment of intracranial aneurysms. It offers Fortress, a modular wall system for hospitals and ambulatory surgery centers. It specializes in soft tissue fixation products and delivering AI-assisted virtual care workflows.
- Revenue in USD (TTM)21.97bn
- Net income in USD3.59bn
- Incorporated1946
- Employees52.00k
- LocationStryker Corp1941 STRYKER WAYPORTAGE 49002United StatesUSA
- Phone+1 (269) 385-2600
- Fax+1 (269) 385-1062
- Websitehttps://www.stryker.com/
Mergers & acquisitions
| Acquired company | SYK:NYQ since announced | Transaction value |
|---|---|---|
| NICO Corp | 6.60% | -- |
| Vertos Medical Inc | 12.69% | -- |
| care.ai Inc | 18.70% | -- |
| MOLLI Surgical Inc | 17.84% | -- |
| Artelon Inc | 14.09% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic PLC | 33.00bn | 4.29bn | 107.87bn | 95.00k | 25.66 | 2.22 | 15.50 | 3.27 | 3.28 | 3.28 | 25.19 | 37.81 | 0.3664 | 2.03 | 5.41 | 347,326.30 | 4.80 | 4.57 | 5.47 | 5.14 | 65.46 | 66.75 | 13.10 | 13.49 | 1.39 | 9.82 | 0.3677 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.91bn | 1.79bn | 132.90bn | 48.00k | 74.54 | 6.42 | 43.96 | 8.35 | 1.21 | 1.21 | 10.73 | 14.05 | 0.4412 | 1.91 | 6.91 | 331,458.30 | 4.96 | 2.50 | 5.85 | 2.91 | 69.09 | 68.84 | 11.24 | 6.47 | 1.02 | 6.02 | 0.3419 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.97bn | 3.59bn | 147.03bn | 52.00k | 41.34 | 7.30 | 31.78 | 6.69 | 9.33 | 9.33 | 57.08 | 52.86 | 0.5368 | 1.56 | 6.27 | 422,576.90 | 8.77 | 6.60 | 10.76 | 7.84 | 63.88 | 63.99 | 16.34 | 13.13 | 1.22 | -- | 0.4345 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Danaher Corp | 23.74bn | 3.93bn | 168.36bn | 61.00k | 43.99 | 3.28 | 27.23 | 7.09 | 5.30 | 5.24 | 32.05 | 71.03 | 0.2821 | 3.39 | 6.11 | 389,213.10 | 4.67 | 5.93 | 5.19 | 6.56 | 59.26 | 58.79 | 16.57 | 19.11 | 1.01 | 21.31 | 0.2546 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Intuitive Surgical, Inc. | 7.87bn | 2.24bn | 192.99bn | 13.68k | 87.10 | 12.38 | 69.97 | 24.53 | 6.22 | 6.22 | 21.81 | 43.75 | 0.4848 | 1.98 | 7.44 | 575,234.00 | 13.93 | 12.42 | 15.63 | 13.83 | 66.98 | 67.60 | 28.73 | 26.31 | 3.42 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Thermo Fisher Scientific Inc | 42.37bn | 6.14bn | 196.16bn | 122.00k | 32.16 | 4.00 | 20.87 | 4.63 | 15.95 | 15.95 | 110.12 | 128.08 | 0.4292 | 4.63 | 4.32 | 347,295.10 | 6.28 | 7.79 | 7.36 | 9.11 | 40.77 | 44.94 | 14.62 | 16.76 | 1.26 | 24.08 | 0.4183 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Abbott Laboratories | 41.22bn | 5.77bn | 201.08bn | 114.00k | 35.15 | 5.05 | 22.36 | 4.88 | 3.30 | 3.30 | 23.57 | 22.94 | 0.5629 | 2.71 | 6.08 | 361,552.60 | 7.88 | 7.72 | 9.77 | 9.39 | 55.81 | 56.73 | 13.99 | 14.39 | 1.14 | 28.44 | 0.2723 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 30.89m | 8.11% |
| Greenleaf Asset Management, Inc.as of 05 Nov 2024 | 21.05m | 5.52% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 17.27m | 4.53% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 14.58m | 3.83% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 10.56m | 2.77% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 9.98m | 2.62% |
| Fundsmith LLPas of 30 Sep 2024 | 7.23m | 1.90% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 7.05m | 1.85% |
| Geode Capital Management LLCas of 30 Sep 2024 | 6.91m | 1.81% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 6.78m | 1.78% |
